Monday, April 15, 2019 5:43:13 PM
TOP 20 GBM INSTITUTIONS
Of the 31 unique institutions that make up these lists, 22 are US-based organizations, eight from Europe, and one from Canada. There are definite research clusters visible with these institutions: in the US, there are clusters in the New England and Mid-Atlantic regions (Harvard, Dana Farber, Massachusetts General Hospital, Brigham & Women's Hospital, Memorial Sloan Kettering, the universities of Pennsylvania and Pittsburgh, Johns Hopkins, and the National Cancer Institute), California (three Universities of California—San Diego, San Francisco, and Los Angeles), Texas (Baylor, the University of Texas MD Anderson Cancer Center, and the University of Texas Health Science Center San Antonio).
In Europe, Germany (German Cancer Research Center, and the universities of Dusseldorf, Heidelberg, Tubingen, and Regensburg), and Switzerland (University of Zurich, University of Lausanne) show this trend.
#7 JOHNS HOPKINS UNIV
#9 UNIV CALIF LOS ANGELES
http://archive.sciencewatch.com/ana/st/glio/institutions/
John Hopkins was NOT involved in DC VAX L Clinicals:
https://clinicaltrials.gov/ct2/show/study/NCT00045968?show_locs=Y#locn
FWIW: Within the Top Ten GBM institutions being positively disposed towards DC VAX L PH3 results as of this date are UCLA and John Hopkins Univ.
Also Heidelberg Univ in Germany was a GBM clinical site.
Univ of Penna was a GBM clinical site.
And one of the two Canadian DC VAX L chosen sites maybe the leading GBM institution in Canada
NOTE: USCF is #2: Instigator of a key lawsuit (was DISMISSED!)against NWBO
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
